Skip to main content
. 2019 Aug 14;2019:1601072. doi: 10.1155/2019/1601072

Figure 4.

Figure 4

Patients with T-CTLA-4(-) +PLR (-) status had superior overall survival. Effects of different levels of T-CTLA-4 (a), I-CTLA-4 (b), PLR (c), and T-CTLA-4(-) +PLR (-) status (d) on the overall survival of ESCC patients without inflammatory diseases. Patients with T-CTLA-4(-) +PLR (-) status had significantly longer overall survival (p = 0.023).